Ready for Answers

If you suspect your patient may have IBS, Crohn's or ulcerative colitis, the IsolateGI panel will be available in Summer 2017.

Review our peer-reviewed articles and join our community to stay up-to-date on our progress.

Join our Community

One Test. Many Answers.

At IQuity, we understand the challenges of diagnosing IBS and IBD early and accurately. IBS can’t be confirmed by visual examination or measured with typical diagnostic tools; therefore, diagnosis requires the physician to obtain a physical, construct a detailed medical history, and monitor the presence of symptoms. A clinical process of elimination allows the provider to arrive at a diagnosis.

IsolateGI offers providers an accurate new tool to identify IBS and IBD at the earliest onset of symptoms, and more importantly, to distinguish among IBS, Crohn’s and ulcerative colitis in their patients. The test uses a simple blood draw and demonstrates accuracy greater then 90%.

Download IBS-IBD Test Overview

Our Research

Irritable bowel syndrome (IBS) affects between 10-20% of the U.S. population and can remain undiagnosed for up to 7 years according to the International Foundation for Functional Gastrointestinal Disorders. While IBS may exhibit symptoms that are similar to inflammatory bowel disease (IBD), these two disease categories are functionally different. Incidence of inflammatory bowel disease in the US is estimated to be 45,000 patients per year and includes ulcerative colitis and Crohn’s disease. 

Diagnostic delays are common for IBS and IBD frequently involving a process of elimination consisting of psychological tests, x-rays, stool tests, and endoscopy to rule in or rule out other suspected diseases. For IBD, the cycle of flares and remissions further complicates early clinical detection when Crohn’s or ulcerative colitis is not suspected because symptoms come and go. Collectively, the average delay is 1-3 years and often a patient is misdiagnosed twice before receiving a diagnosis of IBD. Studies also suggest that IBD cases may be misdiagnosed as IBS in as many as 10% of IBS cases.

Using samples from diagnosed IBS/IBD patients as well as healthy subjects, IQuity’s approach uses machine learning to develop the proprietary algorithm that can accurately identify IBS vs IBD and within IBD, to distinguish between Crohn’s or ulcerative colitis.

IQuity studied more than 500 subjects, including patients with:

  • inflammatory bowel disease: Crohn's and ulcerative colitis 
  • irritable bowel syndrome
  • disease controls: Celiac disease, colorectal cancer
  • healthy patients 


How to Order a Test

IsolateGI will be available in Summer 2017

All of IQuity's tests must be ordered by a provider.

  • Provider registers with IQuity for access to the ordering portal.
  • Patient visits provider who orders the test
  • Patient's blood sample is taken and sent to IQuity CLIA-certified laboratory.
  • IQuity lab process the sample, analyzes the data and returns the result to the provider.

If you are interested in additional information, contact IQuity at iquity.com or call 855.899.9551. To stay up-to-date on our progress, join our community.

Physician Perspective



“Gastrointestinal conditions like IBS and IBD (Crohn’s and ulcerative colitis) can be challenging to diagnose because we rely primarily on a patient’s history and physical, along with other invasive procedures to make a determination. A test that will allow us to make a definitive call early is of value and can help make an accurate diagnosis because we can prescribe patients into an appropriate treatment regimen and diet sooner and minimize irreparable damage.”

Gastroenterologist

Nashville, Tennessee

Peer-Reviewed Articles

Identification of Molecular Biomarkers for Multiple Sclerosis

Quantitative real-time polymerase chain reaction analysis was used to identify a minimum number of genes of which transcript levels discriminated multiple sclerosis patients from patients with other chronic diseases and from controls.

Gene-expression signatures: biomarkers toward diagnosing multiple sclerosis

Results indicate that gene-expression differences in blood accurately exclude or include a diagnosis of MS and suggest that these approaches may provide clinically useful prediction of MS.

Using biomarkers to predict progression from clinically isolated syndrome to multiple sclerosis

Using machine learning techniques, including support vector machines, this study demonstrates that gene expression signatures can accurately identify subjects with a clinically isolated syndrome who later progress to multiple sclerosis.